Created date

Published on

You are here:

MS in the media - 6 January 2017

31 December - 6 January 2017

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

New Year's honours for people with MS

Rhona Elliot, the co-founder of the MS Borders Racing Club that raises money and awareness about MS, has been awarded the MBE. Paralympians Stephanie Millward and Kadeena Cox also both received the MBE

Source: Southern Reporter (Rhona Elliot)
Source: Wiltshire Times (Stephanie Millward)
Source: BBC (all sporting honours)

MS Trust link: Personal stories of living with MS

Lifestyle impact on MS

A small study of people with MS found that 85% of participants didn't eat healthily and many also didn't get enough exercise. The study also looked at smoking and alcohol consumption.

Source: MS News Today

MS Trust link: Lifestyle

Living near busy roads

A Canadian study that found a link between dementia risk and living within 50m of a busy road also looked to see if there was a higher risk of MS but found no association

Source: Guardian

MS Trust link: MS research updates

Magnetic stimulation and brain activity

A small study found that Repetitive Transcranial Magnet Stimulation (rTMS) improved working memory and brain activity in people with MS (none of whom had cognitive symptoms).

Source: National MS Society (USA)

MS Trust link: MS research updates

Gilenya (fingolimod) in Wales

The All Wales Medicines Strategy Group (the Welsh equivalent of NICE) has approved Gilenya as a first line treatment for people with highly active rapidly evolving severe relapsing remitting MS (RES).  This plugs a gap in NICE's guidance, which said the drug should be used as a second line treatment for relapsing MS and didn't mention RES

Source: AWMSG

MS Trust link: Gilenya (fingolimod)